Skip to main content
    C

    Cullinan Oncology LLC (CGEM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.28
    -0.22 (-2.37%)

    Market Cap: $667.39M

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Cullinan Oncology LLC (CGEM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cullinan Oncology LLC (CGEM) has a market cap of $667.39M and an enterprise value of $579.13M. Its share count is up 8.17% from a year earlier. It holds $88.26M more cash than debt, 13.22% of its market cap.

    Total Valuation

    Enterprise value is 13.22% below the market cap, as cash exceeds debt.

    Market Cap$667.39M
    Enterprise Value$579.13M
    Latest price (Nov 17, 2026)$9.28

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.25% in the quarter ended Sep 30, 2026 and grew 4.65% a year over 2 years.

    Shares Outstanding64.60M
    Shares Change (YoY)+8.17%
    Shares Change (QoQ)+4.25%
    Share Count Growth (2Y CAGR)+4.65%

    Price Statistics

    The stock is up 8.48% over 52 weeks and trades 39.62% below its 50-day average.

    Beta (1Y)1.64
    52-Week Change+8.48%
    1-Month Change-33.66%
    3-Month Change-58.81%
    6-Month Change-34.57%
    5-Year Change-32.36%
    Total Return (1Y)+8.48%
    Total Return (3Y CAGR)+1.77%
    Total Return (5Y CAGR)-13.61%
    Return vs SPY (1Y)-2.95%
    Max Drawdown (1Y)-59.59%
    Max Drawdown (3Y)-80.41%
    Sharpe Ratio (1Y)0.10
    Correlation with SPY (1Y)0.28
    50-Day Average$15.37
    200-Day Average$15.79
    52-Week Range$8.23 to $23.19
    RSI (14 Days)27.3
    Average Volume (20 Days)902.19K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.43x current liabilities.

    Current Ratio7.43x
    Quick Ratio7.43x

    Returns and Efficiency

    Return on Assets (ROA)-63.08%
    ROA (5Y Average)-20.80%

    Scores

    CGEM has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$79.00K
    Operating Income-$218.81M
    Pretax Income-$203.47M
    Net Income-$203.47M
    Reported EPS (TTM)-$3.07

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$88.26M
    Total Debt$0
    Net Cash$88.26M
    Net Cash Per Share$1.37
    Working Capital$258.02M
    Shareholder Equity$0
    Book Value Per Share$4.35
    Total Assets$322.56M
    Total Liabilities$41.27M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$165.46M
    FCF Per Share-$2.69
    Depreciation and Amortization$2.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-19.30%
    Tangible Book Per Share Growth (2Y CAGR)-19.30%

    Revenue and profit by year

    Dividends and Yields

    CGEM does not pay a dividend.

    Buyback Yield-0.54%
    Shareholder Yield-0.54%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CGEM

    What is CGEM's market cap?

    Cullinan Oncology LLC has a market cap of $667.39M. Its enterprise value, which adds debt and subtracts cash, is $579.13M.

    How many shares of CGEM are outstanding?

    Cullinan Oncology LLC has 64.60M shares outstanding. The count is up 8.17% from a year earlier.

    Does CGEM pay a dividend?

    No. Cullinan Oncology LLC does not pay a dividend.

    How much debt does CGEM have?

    Cullinan Oncology LLC has $0 of total debt and $88.26M of cash and equivalents, a net cash position of $88.26M.